|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction显示文摘我们以前在范畴 II 长期的细菌的前列腺炎(CBP ) 表明了 fluoroquinolone-macrolide 联合治疗的安全和功效。这研究的目的是回顾地基于 azithromycin 的联合为 CBP 比较 microbiological 和二个处理计划的临床的调查结果(500 mg,三次每周) 与一次每日的 500-mg 或 ciprofloxacin 的 750-mg 剂量(Cipro-500 或 Cipro-750 队,分别地) 。azithromycin 的联合管理(1500 有以 750 的率的 ciprofloxacin 的 mg 星期 −1) ;为 4 个星期而非在 500 的 mg 天 −1 ;为 6 个星期的 mg 天 −1 从 62.35 % 增加了根除率;到 77.32 %并且从 71.76 % 的全部的细菌学的成功;到 85.57 %。在煽动性的白血球计数和浆液的疼痛和 voiding 症状 / 症状和重要减小地的重要减少前列腺特定的抗原(PSA ) 在两个组在整个 18 月的后续经期被支撑。射精的疼痛, haemospermia 和早泄显著地在两个组在 microbiological 根除上被稀释,但是后者在 Cipro-750 队更即时减退了。总共, 59 个 Cipro-750 病人显示出 mild-to-severe 在基线的可勃起的机能障碍(编辑) ,当 22 个病人没在 microbiological 根除上并且在整个后续时期有编辑时。在结论 fluoroquinolone-macrolide,治疗在病原体根除和 CBP 症状变细导致了,包括疼痛, voiding 骚乱和性机能障碍。为 4 个星期的 ciprofloxacin 的一次每日的 750-mg 剂量与 500-mg 剂量相比显示出提高的根除率和更低的煽动性的白血房间计数 6 个星期。我们的结果是开的推进未来的确认。 | Vittorio Magri Emanuele Montanari Visnja Skerk Alemka Markotic Emanuela Marras Antonella Restelli Kurt G Naber Gianpaolo Perletti | 2011 | Asian Journal of Andrology2011，13，6： | 12 |
| 2 | The Humoral Pattern Recognition Molecule PTX3 Is a Key Component of Innate Immunity against Urinary Tract Infection显示文摘 | Sébastien Jaillon Federica Moalli Bryndis Ragnarsdottir Eduardo Bonavita Manoj Puthia Federica Riva Elisa Barbati Manuela Nebuloni Lidija Cvetko Krajinovic Alemka Markotic Sonia Valentino Andrea Doni Silvia Tartari Giorgio Graziani Alessandro Montanelli Y | 2014 | Immunity2014，，4： | 1 |
| 3 | Total-factor energy efficiency in the EU countries显示文摘 | NELA V ALEMKA S | 2012 | Journal of Economics and Busi- ness2012，30，2： | 1 |
| 4 | Antibiotic resistance of Helicobacter pylori in pediatric patients — 10 years’ experience显示文摘 | Iva Hojsak Tea Kos Jelena Duman?i? Zrinjka Mi?ak Oleg Jadre?in Alemka Jaklin Kekez Amarela Luki? Grli? Sanja Kola?ek | 2012 | European Journal of Pediatrics2012，，9： | 1 |
| 5 | 流感与COVID-19患者的免疫球蛋白G糖基化差异显示文摘The essential role of immunoglobulin G(IgG)in immune system regulation and combatting infectious diseases cannot be fully recognized without an understanding of the changes in its N-glycans attached to the asparagine 297 of the fragment crystallizable(Fc)domain that occur under such circumstances.These glycans impact the antibody stability,half-life,secretion,immunogenicity,and effector functions.Therefore,in this study,we analyzed and compared the total IgG glycome—at the level of individual glycan structures and derived glycosylation traits(sialylation,galactosylation,fucosylation,and bisecting Nacetylglucosamine(GlcNAc))—of 64 patients with influenza,77 patients with coronavirus disease 2019(COVID-19),and 56 healthy controls.Our study revealed a significant decrease in IgG galactosylation,sialylation,and bisecting GlcNAc(where the latter shows the most significant decrease)in deceased COVID19 patients,whereas IgG fucosylation was increased.On the other hand,IgG galactosylation remained stable in influenza patients and COVID-19 survivors.IgG glycosylation in influenza patients was more time-dependent:In the first seven days of the disease,sialylation increased and fucosylation and bisecting GlcNAc decreased;in the next 21 days,sialylation decreased and fucosylation increased(while bisecting GlcNAc remained stable).The similarity of IgG glycosylation changes in COVID-19 survivors and influenza patients may be the consequence of an adequate immune response to enveloped viruses,while the observed changes in deceased COVID-19 patients may indicate its deviation. | Marina Kljakovic-Gašpic Batinjan Tea Petrovic Frano Vuckovic Irzal Hadz ibegovic Barbara Radovani Ivana Jurin LovorkaÐerek Eva Huljev Alemka Markotic Ivica Lukšic Irena Trbojevic´-Akmacic Gordan Lauc Ivan Gudelj Rok Civljak | 2023 | Engineering2023，，7： | 0 |
| 6 | Combined liver-kidney transplantation for rare diseases显示文摘Combined liver and kidney transplantation(CLKT)is indicated in patients with failure of both organs,or for the treatment of end-stage chronic kidney disease(ESKD)caused by a genetic defect in the liver.The aim of the present review is to provide the most up-to-date overview of the rare conditions as indications for CLKT.They are major indications for CLKT in children.However,in some of them(e.g.,atypical hemolytic uremic syndrome or primary hyperoxaluria),CLKT may be required in adults as well.Primary hyperoxaluria is divided into three types,of which type 1 and 2 lead to ESKD.CLKT has been proven effective in renal function replacement,at the same time preventing recurrence of the disease.Nephronophthisis is associated with liver fibrosis in 5%of cases and these patients are candidates for CLKT.In alpha 1-antitrypsin deficiency,hereditary C3 deficiency,lecithin cholesterol acyltransferase deficiency and glycogen storage diseases,glomerular or tubulointerstitial disease can lead to chronic kidney disease.Liver transplantation as a part of CLKT corrects underlying genetic and consequent metabolic abnormality.In atypical hemolytic uremic syndrome caused by mutations in the genes for factor H,successful CLKT has been reported in a small number of patients.However,for this indication,CLKT has been largely replaced by eculizumab,an anti-C5 antibody.CLKT has been well established to provide immune protection of the transplanted kidney against donor-specific antibodies against class I HLA,facilitating transplantation in a highly sensitized recipient. | Mladen Knotek Rafaela Novak Alemka Jaklin-Kekez Anna Mrzljak | 2020 | World Journal of Hepatology2020，12，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员